Table 1 Recently started or planned clinical trials

1

China

ACLF

N/A

N/A

1–10 × 10⁵/kg

4

Peripheral vein

I/II

Randomized/open label

2

China

ACLF

N/A

N/A

0.1–1 × 10⁶/kg

3

Peripheral vein

N/A

Randomized/double blind

3

Germany

ACLF

Allo

Skin (ABCB5+ cells)

2 × 10⁶/kg

3

Peripheral vein

I/II

Non-randomized/open label

4

China

Cirrhosis

N/A

N/A

N/A

N/A

N/A

I/II

Non-randomized/open label

5

China

Cirrhosis

Allo

UC

1.5 × 10⁶/kg

2~4

Peripheral vein

II

Non-randomized/open label

6

China

Cirrhosis (HBV, HCV)

N/A

N/A

1 × 10⁶/kg

4

Peripheral vein

N/A

Randomized/single blind

7

Japan

Cirrhosis (NASH, HCV)

Allo

AD

N/A

1

Peripheral vein

I/II

Non-randomized/open label

8

Taiwan

ACLF

Allo

AD

0.5–2 × 10⁶/kg

N/A

Peripheral vein

I

Non-randomized/open label

9

Singapore

Cirrhosis

Auto

BM

0.5–1 × 10⁶/kg

N/A

Peripheral vein

I/II

Non-randomized/open label

10

China

Alcoholic liver cirrhosis

Auto

BM

5 × 10⁷ cells/10 ml

1

Hepatic artery

I

Non-randomized/open label

11

China

Cirrhosis (HBV)

Allo

UC

6 × 10⁷ (30 ml)

N/A

Peripheral vein

I

Non-randomized/open label

12

China

PBC

N/A

N/A

0.1–1 × 10⁶/kg

3

Peripheral vein

N/A

Randomized/double blind